Clinical kinetics of 1,4-dihydroxy-5,8-bis [[2- [(2-hydroxyethyl)amino ]ethyl] amino]-9,10-anthracenedione
- 28 February 1982
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacology & Therapeutics
- Vol. 31 (3) , 312-316
- https://doi.org/10.1038/clpt.1982.39
Abstract
The clinical kinetics of 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride (DHAQ) are reported. DHAQ, 1-3 mg/m2, was administered as an i.v. bolus to 6 patients with metastatic cancer. Plasma clearance of the drug followed a biphasic pattern with a harmonic mean initial half-life (t1/2) of 13.7 min and a terminal t1/2, of 37.4 h. Recovery of unchanged drug in the urine was 6.8% at 24 h and 7.3% at 72 h; the corresponding recovery of total radioactivity was 9.4% and 11.3%. Apparent volume of distribution of DHAO was .apprx. 13.8 .+-. 2.9 l/kg. Total clearance was 238.7 ml/kg per h, twice the creatinine clearance.This publication has 5 references indexed in Scilit:
- Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenedionesJournal of Medicinal Chemistry, 1979
- EXPERIMENTAL ANTI-TUMOR ACTIVITY OF AMINOANTHRAQUINONES1979
- ACTIVITY OF A NOVEL ANTHRACENEDIONE, 1,4-DIHYDROXY-5,8-BIS[[[2-[(2-HYDROXYETHYL)AMINO]ETHYL]AMINO]]-9,10-ANTHRACENEDIONE DIHYDROCHLORIDE, AGAINST EXPERIMENTAL-TUMORS IN MICE1979
- EFFECTS OF 9,10-ANTHRACENEDIONE, 1,4-BIS[[2-[(2-HYDROXYETHYL)AMINO]-ETHYL]AMINO]-DIACETATE ON CELL-SURVIVAL AND CELL-CYCLE PROGRESSION IN CULTURED MAMMALIAN-CELLS1979
- Evaluation of the binding of some substituted anthraquinones and naphthacenequinones to DNAJournal of Pharmacy and Pharmacology, 1976